The Zhitong Finance App learned that Debon Securities released a research report saying that the biomedical industry chain shows a gradual transmission rhythm of “demand recovery → upstream life science → CXO”. As an additional variable, AIDD is driving upstream life science demand in reverse through closed loop of dry and wet experiments, thus gradually being transmitted to the CXO industry. With the passage of time and the continuous emergence of new technologies, AIDD is expected to empower the entire pharmaceutical industry, and the bank believes that the future of AIDD can be expected.
The main views of Debon Securities are as follows:
CXO
On the demand side, the core variables that suppress the sector are being reversed. Global biomedical investment and financing margins have improved, and overseas pharmaceutical companies' R&D budgets and outsourcing penetration rates have risen overall; orders come before revenue, revenue comes before profit, and orders from leading companies have taken the lead in improving. On the supply side, the industry pattern has turned clear, excess production capacity in the early stages has gradually been eliminated, and the CAPEX industry has begun a new round of expansion. Looking ahead to 2027 and the future, the bank believes that the CXO industry stands at a new starting point of demand. As new molecules and other requirements for process development and experimental design capabilities continue to increase, China's CXO industry is expected to continue to maintain international competitiveness through the continuous accumulation of “engineer dividends” and early R&D experience. Recommended attention: Yao Ming Kangde, Yao Ming Biology, Pharmaceutical Syndication, Kanglong Chemical, Gloria Ying, Haoyuan Pharmaceutical, Tiger Pharmaceuticals, Medicis, Zhaoyan New Pharmaceutical, Propron Pharmaceuticals, etc.
Upstream life sciences
The bank is optimistic that the upstream life science sector will return to the upward channel. As the total amount of domestic innovative drug BD continues to rise, compounding the continuous development of domestic basic research, the future core drive is expected to come from a recovery in research demand and a recovery in investment in innovative drug research. At the same time, AI will export candidate molecules in batches under AIDD dry and wet closed loop, further boosting orders for high-throughput verification consumables such as protein, gene synthesis, culture media, and model animals, forming an important increase in sector elasticity. Domestic substitution is right. As domestic substitution rates continue to rise in the future, the bank expects the overall upstream life science market to rise further. Recommended attention: Kingsley Biotech, Bepsis, Haoyuan Pharmaceuticals, Bide Pharmaceuticals, Medicinal Health Biotech, Bioosetu, Near Shore Protein, etc.
Optimistic about the long-term development of the AIDD industry
The AIDD industry is still in the early stages of development. The potential market space is large. Generative AI and big model technology are driving drug design from “assisted screening” to “generation from scratch”, and national policies are also continuously advancing the development of AI4S. Over time and the continuous emergence of new technologies, AIDD is expected to empower the entire pharmaceutical industry. The bank believes that AIDD can look forward to the future. Recommended attention: Insili Intelligence, Jingtai Holdings, Jietai Technology, etc.
Risk warning: policy changes, geographical disturbances, clinical failure, risk of BD termination, risk of investment contraction, etc.